Spero Therapeutics | ARS: Annual Report to Security Holders
Apr 16 16:21 ET
Spero Therapeutics | DEFA14A: Others
Apr 16 16:21 ET
Spero Therapeutics | DEF 14A: Definitive information statements
Apr 16 16:17 ET
Spero Therapeutics | 8-K: Current report
Mar 29 16:17 ET
Spero Therapeutics | EFFECT: Others
Mar 25 06:03 ET
Spero Therapeutics | CORRESP: CORRESP
Mar 20 13:56 ET
Spero Therapeutics | UPLOAD: Others
Mar 20 13:56 ET
Spero Therapeutics | S-3: Registration statement for specified transactions by certain issuers
Mar 15 16:42 ET
Spero Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Mar 15 16:24 ET
Spero Therapeutics | 10-K: Annual report
Mar 13 16:15 ET
Spero Therapeutics | 8-K: Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business Update
Mar 13 16:11 ET
Spero Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-Anson Funds Management LP(8.1%),Anson Management GP LLC(8.1%), etc.
Feb 14 17:38 ET
Spero Therapeutics | 8-K: Current report
Feb 9 16:12 ET
Spero Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Keutzer Timothy
Feb 5 20:59 ET
Spero Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Mahadevia Ankit
Feb 5 20:54 ET
Spero Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer JOSEPH TAMARA L
Feb 5 20:54 ET
Spero Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer HAMED KAMAL
Feb 5 20:49 ET
Spero Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Rajavelu Esther
Feb 5 20:49 ET
Spero Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Shukla Sath
Feb 5 20:44 ET
Spero Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
Feb 5 16:54 ET
No Data
No Data